Asset Details
Do you wish to reserve the book?
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection
Do you wish to request the book?
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection
2022
Overview
Oral antibacterial agents that are active against antimicrobial-resistant bacteria are needed. In this double-dummy, randomized, controlled trial, tebipenem pivoxil hydrobromide (an orally bioavailable carbapenem) was noninferior to intravenous ertapenem for the treatment of complicated urinary tract infection.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Anti-Bacterial Agents - administration & dosage
/ Anti-Bacterial Agents - adverse effects
/ Anti-Bacterial Agents - therapeutic use
/ Carbapenems - administration & dosage
/ Carbapenems - adverse effects
/ Carbapenems - therapeutic use
/ COVID-19
/ Diarrhea
/ Drug Resistance, Multiple, Bacterial
/ Ertapenem - administration & dosage
/ Humans
/ Patients
/ Pyelonephritis - drug therapy
/ Urinary Tract Infections - drug therapy
/ Urinary Tract Infections - microbiology
/ Urology
/ UTI
